SYDNEY, AUSTRALIA–(Marketwired – June 23, 2016) – Simavita Limited (“Simavita” or the “Company“) (TSX VENTURE:SV)(ASX:SVA) is pleased to announce the results of the Special Meeting of the Company’s shareholders which was held at 10:00 am today (Australian Eastern Standard Time) in Sydney, Australia. All nine resolutions that were put before the meeting were passed on a show of hands. Details of the proxy votes received by the Company in relation to each resolution in the notice of special meeting and information circular are attached.
For further information, please check our website (www.simavita.com).
About Simavita
Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ incontinence diagnostic tool kit which is an instrumented incontinence assessment application that provides evidence based incontinence management care plans to the residential aged care market.
About SIM™
SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect record and report incontinence events during a compulsory or recommended assessment period in residential aged care sites to develop an evidence-based incontinence care plan.
Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.
The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.
| SIMAVITA LIMITED | |||||||||
| SPECIAL MEETING OF | |||||||||
| SHAREHOLDERS HELD | |||||||||
| ON JUNE 23, 2016 | |||||||||
| PROXY RESULTS | |||||||||
| RESOLUTIONS | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | |||||||
| FOR | AGAINST | ABSTAIN | EXCLUDED | NON VOTE | FOR | AGAINST | WITHHELD/ ABSTAIN | ||
| 1. | Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds | 55,646,847 | 29,444 | 5,127 | 0 | 0 | 99.94% | 0.05% | 0.01% |
| 2. | Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds for Dussman Pty. Ltd. | 17,481,916 | 34,244 | 5,127 | 38,160,131 | 0 | 99.78% | 0.20% | 0.03% |
| 3. | Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds for Holland Family Trust | 55,614,047 | 32,244 | 5,127 | 30,000 | 0 | 99.93% | 0.06% | 0.01% |
| 4. | Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds for Bingham Investments Pty. Ltd. | 55,644,047 | 32,244 | 5,127 | 0 | 0 | 99.93% | 0.06% | 0.01% |
| 5. | Approval and Authorization of the operation of the Conversion Mechanism in the Convertible Note Deeds for the Michael Brown Superannuation Fund | 55,642,047 | 34,244 | 5,127 | 0 | 0 | 99.93% | 0.06% | 0.01% |
| 6. | Approval and Authorization of the issuance of up to 138,740,000 CDIs | 45,739,319 | 41,571 | 0 | 9,900,528 | 0 | 99.91% | 0.09% | 0.00% |
| 7. | Approval and Authorization to grant to Mr. Michael Spooner up to 7,603,422 unlisted options | 54,476,323 | 995,429 | 109,666 | 0 | 100,000 | 98.01% | 1.79% | 0.20% |
| 8. | Approval and Authorization to grant to Dr. Gary Pace up to 7,603,422 unlisted options | 54,576,323 | 995,429 | 109,666 | 0 | 0 | 98.02% | 1.79% | 0.20% |
| 9. | Approval and Authorization to increase the total amount of potential aggregate directors’ fees which may be paid to non-executive directors | 49,405,237 | 5,840,046 | 433,485 | 0 | 2,650 | 88.73% | 10.49% | 0.78% |
Ms Peta Jurd
+61 421 466 653
pjurd@simavita.com
www.simavita.com